Tethis s.r.l., a Milan, Italy-based company committed to developing novel nanostructured thin layers to apply to innovative tools for environmental monitoring, diagnostics and drug discovery, has received a €3m investment from Atlante Ventures. 
As a result of the transaction, Atlante Ventures will take a 16% stake in the company.
Tethis is controlled owned by Genextra S.p.A., a private biopharmaceutical group headquartered in Milan primarily dedicated to the discovery and development of innovative therapeutics for the cure of cancer, age-related and metabolic disorders.
The capital will be used to complete the development of microFind(tm), an innovative device for the detection of genetic aberration by means of Fluorescent in Situ Hybridization (FISH) technology.
FinSMEs
06/07/2010